Chinese herbal compound composition for treating lung diseases and preparation method thereof

Abstract

The invention discloses a Chinese herbal compound composition for treating lung diseases and a preparation method thereof. The Chinese herbal compound composition is prepared from, by weight, 3-10 parts of sun-dried ginseng, 5-16 parts of astragalus membranaceus, 4-12 parts of rhizoma chuanxiong, 1-20 parts of allium macrostemon, 12-15 parts of schisandra chinensis, 1-35 parts of semen lepidii and 15-30 parts of lumbricus. The preparation method of the Chinese herbal compound composition includes the steps of obtaining a first raw material by extracting sun-dried ginseng and astragalus membranaceus to obtain first thick paste and conducting pressure reduction band drying and smashing on the first thick paste, obtaining a second raw material by mixing decoction dregs with rhizoma chuanxiong, lumbricusm semen lepidii, schisandra chinensis and allium macrostemon to obtain second thick paste and conducting pressure reduction band drying and smashing on the second thick paste, mixing the first raw material, the second raw material and acceptable auxiliaries on pharmacy, and preparing the Chinese herbal compound composition for treating lung diseases. The Chinese herbal compound composition has the advantages that the transfer rate of astragaloside in the raw materials is high, the utilization rate of effective components in traditional Chinese medicine is high, and medical value of traditional Chinese medicine raw materials can be brought into full play.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a compound traditional Chinese medicine composition for treating lung diseases, and the lung diseases are chronic obstructive pulmonary disease syndrome of lung-kidney qi deficiency and phlegm-stasis obstruction of the lungs. Background technique [0002] Chronic Obstructive Pulmonary Disease (COPD), referred to as COPD, is a disease with high morbidity, disability and mortality. Due to long-term airway obstruction, chronic obstructive pulmonary disease causes alveolar hypoxia and carbon dioxide retention, which promotes pulmonary vasoconstriction, thereby causing pulmonary hypertension (COPD syndrome of phlegm and stasis obstructing the lung). With the increase of pulmonary hypertension, the The burden on the right heart eventually leads to hypertrophy and enlargement of the right heart, eventually forming cor pulmonale. [0003] At present, th...

AI Technical Summary

Problems solved by technology

[0003] At present, there are nifedipine tablets and other drugs for the treatment of COPD with phlegm and blood stagnation in the lung syndrome, but its curative effect on pulmonary arterial hypertension is not very satisfactory

In addition, its drug effect time is short, it has large fluctuations in blood pressure, and it still has negative muscle strength and negative conduction effects, which will also increase the mortality of patients with coronary heart disease.

In addition, the existing western medicines can only cure the symptoms but not the root cause, and these medicines have many side effects, especially serious damage to the liver and kidneys, which only relieve the symptoms and cannot achieve the purpose of a complete cure

[0004] In the prior art, the traditional Chinese medicine composition used to treat chronic obstructive pulmonary disease with phlegm and blood stasis syndrome is disclosed by the specification of Chinese invention patent CN102038841A. The method disclosed in this patent is to extract the raw materials with water, and the astragaloside IV in the raw materials The rate is low, resulting in the loss of active ingredients of traditional Chinese medicine, failing to give full play to the medicinal value of raw materials of traditional Chinese medicine

Images